PROC Stock Forecast 2025-2026
Distance to PROC Price Targets
PROC Price Momentum
🤔 Considering Procaps (PROC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest PROC Stock Price Targets & Analyst Predictions
PROC has shown a year-to-date change of -67.5% and a 1-year change of -75.8%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PROC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PROC Analyst Ratings
PROC Price Target Range
Latest PROC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PROC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 6, 2023 | Brookline Capital | Kemp Dolliver | Hold | Downgrade | $4.50 |
Procaps Group S.A. (PROC) Competitors
The following stocks are similar to Procaps based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Procaps Group S.A. (PROC) Financial Data
Procaps Group S.A. has a market capitalization of $113.95M with a P/E ratio of 1.5x. The company generates $414.10M in trailing twelve-month revenue with a 12.6% profit margin.
Revenue growth is +7.3% quarter-over-quarter, while maintaining an operating margin of +11.1% and return on equity of +373.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Procaps Group S.A. (PROC) Business Model
About Procaps Group S.A.
Pharmaceutical company specializing in innovative health products.
Procaps Group generates revenue through the development, manufacturing, and commercialization of pharmaceutical and nutritional products. Its business model is bolstered by a strong emphasis on research and development, allowing it to introduce advanced dosage forms and drug delivery systems to the market.
The company operates globally, supplying products to over 50 countries and impacting various sectors such as healthcare, wellness, and nutrition. Procaps Group's focus on technological advancements and strategic partnerships positions it as a leader in addressing global health challenges.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
5,500
CEO
Mr. Ruben Minski
Country
Luxembourg
IPO Year
2019
Website
www.procapsgroup.comProcaps Group S.A. (PROC) Latest News & Analysis
Nasdaq will remove Procaps Group for failing to meet financial reporting standards, effective February 4, highlighting challenges in regulatory compliance for businesses.
The removal of Procaps Group from Nasdaq signals regulatory compliance risks, potentially impacting investor confidence and highlighting challenges for companies in meeting financial standards.
Procaps Group (NASDAQ: PROC) will be delisted from Nasdaq due to non-compliance with financial reporting rules. Shares will begin trading on the OTC Markets starting February 4, 2025.
Delisting from Nasdaq signals financial instability and lack of transparency, likely leading to decreased investor confidence and a drop in share value as trading moves to OTC markets.
Procaps Group Receives Additional Delinquency Letter
2 months agoProcaps Group, S.A. (NASDAQ: PROC) received notice from Nasdaq on December 31, 2024, regarding an additional filing delinquency for its interim financial statements for June 30, 2024.
Procaps Group's filing delinquency signals potential regulatory issues, which could affect investor confidence, stock price, and market perception of the company's financial health.
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
2 months agoProcaps Group (NASDAQ: PROC) announced changes to its Board of Directors, restructuring of committees, and updates to its executive leadership following its recent Shareholders Meeting.
Changes in board composition and executive leadership at Procaps Group may impact company strategy and performance, influencing investor sentiment and stock valuation.
Procaps Group, S.A. (NASDAQ: PROC) announced key strategic transactions and governance updates to enhance its financial position and support long-term growth on December 3, 2024.
Procaps' strategic transactions and governance updates signal a stronger financial position, potentially enhancing growth prospects and investor confidence in the company's future performance.
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
4 months agoProcaps Group (NASDAQ: PROC) faces potential delisting from Nasdaq due to failing to timely file its Form 20-F for 2023. The company can request a hearing to contest this action.
Procaps Group's potential delisting from Nasdaq due to late filing raises concerns about its financial health and compliance, impacting investor confidence and stock value.
Frequently Asked Questions About PROC Stock
What is Procaps Group S.A.'s (PROC) stock forecast for 2025?
Analyst forecasts for Procaps Group S.A. (PROC) are not currently available. The stock is trading at $0.76.
Is PROC stock a good investment in 2025?
According to current analyst ratings, PROC has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PROC stock?
Price predictions from Wall Street analysts for PROC are not currently available. The stock is trading at $0.76.
What is Procaps Group S.A.'s business model?
Procaps Group generates revenue through the development, manufacturing, and commercialization of pharmaceutical and nutritional products. Its business model is bolstered by a strong emphasis on research and development, allowing it to introduce advanced dosage forms and drug delivery systems to the market.
What is the highest forecasted price for PROC Procaps Group S.A.?
Price targets from Wall Street analysts for PROC are not currently available. The stock is trading at $0.76.
What is the lowest forecasted price for PROC Procaps Group S.A.?
Price targets from Wall Street analysts for PROC are not currently available. The stock is trading at $0.76.
What is the overall PROC consensus from analysts for Procaps Group S.A.?
The overall analyst consensus for PROC is neutral. Out of 1 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are PROC stock price projections?
Stock price projections, including those for Procaps Group S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
